Alcon Ventures

Alcon Ventures is the corporate venture capital arm of Alcon, the Geneva-based eye care company that operates as one of the largest pure-play ophthalmology businesses globally. The fund focuses exclusively on disruptive ophthalmic surgical devices and vision care therapeutics, mirroring the parent’s two pillars: surgical equipment for cataract and vitreoretinal procedures, and vision care including contact lenses and dry eye products. Founders working on intraocular lenses, phacoemulsification advances, retinal surgical devices, ocular drug delivery, contact lens innovations, or dry eye therapeutics fit the thesis tightly.

The fund invests at Series A and Series B with check sizes of $5M to $25M, on the larger end of this batch. It is headquartered in Switzerland with global reach. The mandate spans medical devices and pharma therapeutics, both filtered through an ophthalmology lens. No AI focus is stated.

Founders should expect strategic diligence that weighs commercial fit with Alcon’s surgical and vision care channels and the potential for co-development or eventual acquisition. A clear regulatory plan for either device or pharma pathway, surgeon or optometrist engagement, and clinical evidence are essential. Limited public information is available about specific partner contacts and detailed portfolio composition, so referrals via ophthalmologic KOLs, ASCRS or AAO networks, or Alcon business development are typically the most credible routes in.